Skip to content

comparison of depakin and phenytoin in serial seizures

Comparison efficacy of depakin and phenytoin in aborting serial seizures.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2013012012208N1
Enrollment
60
Registered
2013-04-28
Start date
2013-02-03
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Epilepsy. Generalized idiopathic epilepsy and epileptic syndromes

Interventions

Intervention 1: Administration Depakin (Na valproate) IV at dose 20mg/kg stat then 1mg/kg/hour for 24 hours. Intervention 2: Administration Phenytoin (IV) at dose 18 mg/kg.
Treatment - Drugs
Administration Depakin (Na valproate) IV at dose 20mg/kg stat then 1mg/kg/hour for 24 hours
Administration Phenytoin (IV) at dose 18 mg/kg

Sponsors

Shiraz University Of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1-age>18y/o 2- SS is defined as 2 generalized tonic clonic seizures in 1 hour or more than 2 generalized tonic clonic seizures in 24 hours. Patients should regain full level of consciousness between attacks. Exclusion criteria: 1-Status epilepticus 2-Pregnancy 3-Hepatic failure 4-renal failure 5-Younger than 18 years old phenytoin such as heart disease, drug sensivity, systolic blood pressure less than 100mmhg, heart rate less than 60/min

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Number of seizures during 24 hours after treatment. Timepoint: 24 hours. Method of measurement: observe patient and completing a form.

Secondary

MeasureTime frame
Cardiac rhythm. Timepoint: continuous monitoring. Method of measurement: Heart minitoring device.;Blood pressure. Timepoint: continuous monitornig. Method of measurement: Digital blood pressure manitor.;Haert Rate. Timepoint: Continuous Monitoring. Method of measurement: Haert monitoring device.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactRaeyat Mohammed Reza

Department of Neurology, Shiraz University Of Medical Sciences

raeyatr@yahoo.com+98 71 1612 1065

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026